natgillin/translations-raw huggingface dataset:
iii) a third CDR comprising SEQ ID NO:5; and a light chain variable region comprising: 
varijabilnu regiju lakog lanca koja sadrži SEQ ID NO:10; i kovalentno vezan dio lijeka.
The reaction mixture is stirred at room temperature for 40 minutes and then cooled to −70° C. whereupon methyl iodide (1.25 ml, 20 mmol) is added dropwise. 
Reakcijsku smjesu se miješa 40 minuta pri sobnoj temperaturi i zatim se ohladi na -70%C, nakon čega se doda kap po kap metil jodid (1,25 ml, 20 mmolova).
Cannabinoid receptor modulators may reduce anxiety or depression; therefore, the compounds described in this application may be used in combination with anti-anxiety agents or antidepressants. 
Modulatori kanabinoid receptora mogu smanjiti anksioznost ili depresiju; radi toga, spojevi opisani u ovoj prijavi mogu se upotrijebiti u kombinaciji sa sredstvima protiv anksioznosti ili antidepresivima.
In a further aspect the teaching relates to a method of inhibiting growth and/or killing of a cell expressing CLD18, preferably CLD18A2, comprising contacting the cell with an effective amount of an antibody of the teaching and/or a conjugate thereof with a therapeutic agent. 
Protutijelo sukladno patentnom zahtjevu 1 i/ili konjugat sukladno patentnom zahtjevu 3 za uporabu u postupku za inhibiciju rasta i/ili uništavanje stanice koja eksprimira CLD18A2.
represents oxygen atom substituted by a saturated and linear or branched hydrocarbon chain comprising from 2 to 4 carbon atoms, oxygen atom substituted by a saturated and linear or branched hydrocarbon chain comprising from 5 to 10 carbon atoms, a cycloalkyloxy, a cycloalkylalkoxy, an aryloxy or a mono- or dialkylamino. 
R2 predstavlja atom kisika, supstituiran sa zasićenim i nerazgranatim ili razgranatim ugljikovodičkim lancem, koji sadrži od 2 do 4 atoma ugljika, atom kisika, supstituiran sa zasićenim i nerazgranatim ili razgranatim ugljikovodičkim lancem, koji sadrži od 5 do 10 atoma ugljika, cikloalkiloksi, cikloalkilalkoksi, ariloksi ili mono- ili dialkilamino.
Accordingly, there is a need for a method of recycling solid supports for cultivation of anchorage-dependent cells in situ, said method allowing maintaining a protein productivity level comparable to the protein productivity level obtained with non-recycled supports. 
Sukladno tomu, postoji potreba za postupkom za reciklažu krutih potpora za in situ uzgoj stanica koje potrebuju pričvršćivanje, pri čemu će spomenuti postupak omogućavati održavanje proteinske produktivnosti na onoj razini koja se može usporediti s protemskom produktivnošću koja je dobivena s potporama koje se ne recikliraju.
In fig. 2, the drum 220 is shown in a first rotational position with the movable element in an advanced position and pointing downwards, and with a returnable object/ item 10 entered into the input receiving space or area 210 to be placed on an upward facing region of the outer circumferential surface 228 of the drum 220. 
- namjensko ulazno područje (210) za primitak povratnih artikala koji se trebaju postaviti na gornji obodni dio bubnja kad je bubanj u navedenom prvom rotacijskom položaju, pri čemu je ulazno područje smještena iznad navedenog bubnja, pogon elementa je prilagođen da pozicionira element u uvučenom položaju kad se bubanj nalazi u drugom rotacijskom položaju s udubljenjem u bubnju okrenutim prema gore prema ulaznom području, i
A compound, or a pharmaceutically acceptable salt thereof, for use according to claim 5, wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time se što bolest bira iz skupine koju čine kronična opstruktivna plućna bolest, kronični bronhitis, astma, kronična začepljenost dišnih puteva, plućna fibroza, plućni emfizem i alergijski rinitis.
A process according to claim 14, characterised in that the bottom part of the chamber is opened for the discharge of sqlids. 
Postupak prema zahtjevu 13, naznačen time da je donji dio komore otvoren radi ispuštanja krutih tvari.
Atomiser according to claims 2, 22 and 25, characterised in that the locking device (78) is arranged on the part or that in the first and/or second locked state rotation of the part relative to the atomiser (1) and/or operation of the locking element (8) are blockable. 
Raspršivač prema zahtjevima 2, 22 1 25, naznačen time, da je uređaj za zakočenje (78) smješten na dijelu koji se odnosi na raspršivač (1) ili da se rotacija dijela koji se odnosi na raspršivač (1) i/ili djelovanje elementa za zaključavanje (8) mogu blokirati.
A compound represented by formula I, a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof; 
PATENTNI ZAHTJEVI 1. Spoj predstavljen formulom I, N-oksid, adicijska sol, kvaterni amin, metalni kompleks ili njegov stereokemijski izomerni oblik;
The siRNA according to claim 1 or 2, wherein 1 to 10 consecutive nucleotides excluding an overhang nucleotide from the 3' terminus of the sense strand of the siRNA are converted into DNA. 
SIRNA u skladu s patentnim zahtjevom 1, naznačena time, da se 1 do 10 uzastopnih nukleotida s iznimkom izbočenog nukleotida 12 3' terminusa sens lanca siRNA, pretvaraju u DNA.
The use of any of the Claims 1 to 10, wherein said composition comprising a dried, nonviable selenium-enriched yeast wherein the total selenium content of said yeast comprises two percent or less inorganic selenium is administered to said subject so as to provide 200 µg of selenium to said subject each day. 
Primjena bilo kojeg od Zahtjeva 1-13, naznačena time da navedeni pripravak sadrži suhi, neživi kvasac obogaćen selenom, u čijem ukupnom sadržaju selena ima dva posto ili manje neorganskog selena, a koji je zajedno formuliran s antioksidansom.
The method of claim 13, wherein the G-CSF is human or bovine G-CSF, with an initial methionine amino residue at position 1, respectively. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je G-CSF ljudski ili goveđi G- CSF, uz odgovarajući mogući početni ostatak aminokiseline metionina na položaju -1.
reacting Compound (A) 
CI kako bi se dobilo Spoj (H)
A method of improving body composition, the improvement of body composition being selected from the group consisting of increased lean body mass, decreased fat mass relative to total body weight, decreased visceral fat mass relative to total body weight, a decreased visceral fat mass relative to total fat mass, decreased fat accumulation and increased muscle mass, the method comprising administering to a preterm and/or small for gestational age infant a nutritional composition comprising carbohydrates, protein and lipid, wherein the lipid is present in the form of lipid globules comprising: 
15. Nutritivni pripravak prema bilo kojem od zahtjeva 1-13 za uporabu u poboljšanju tjelesne građe, poboljšanje tjelesno građe se odabire iz skupine koju čine povećanje nemasnog dijela tjelesne težine, smanjenje masne težine u odnosu na ukupnu tjelesnu težinu, smanjenje tkivne masne težine tkiva u odnosu na ukupnu tjelesnu težinu, smanjenje tkivne masne težine tkiva u odnosu na ukupnu masnu težinu, smanjenje nakupljanja masti i povećanje mišićne mase, povećanje koštane mase i povećanje mineralne gustoće kostiju.
As for the stereochemistry of such asymmetric carbon atoms, they may independently be in either (R) and (S) configuration, and the derivative may exist as stereoisomers such as optical isomers, or diastereoisomers. 
Å to se tiče stereokemije takvih asimetričnih atoma ugljika, oni neovisno mogu biti bilo u (R) ili (S) konfiguraciji, a njihovi derivati mogu postojati kao stereoizomeri, poput optičkih izomera ili dijastereoizomera.
The process for preparing a vaccine composition as claimed in claim 17, wherein the conjugate obtained in a) is combined with diphtheria toxoid, tetanus toxoid, and acellular Bordetella pertussis antigens toxoid, pertactin and filamentous hemagglutinin. 
Postupak za pripravu pripravka cjepiva prema zahtjevu 12 ili 13, naznačen time da se konjugat dobiven u koraku b) kombinira s toksoidom difterije, toksoidom tetanusa, 1 3 acelulama antigena Bordetella pertussis, koji su toksoid, pertaktin 1 filamentozni hemaglutinin.
The method according to claim 4, wherein the combined duration of the maintenance period (iii) with the Cladribine-free period (iv) is about 1 year and the total dose of Cladribine administered during this year of treatment is about 1.7 mg/kg. 
Uporaba ili proizvod za uporabu prema zahtjevu 6 ili 7 naznačena time da je kombinirano trajanje perioda održavanja (ili) sa periodom bez Kladribina (iv) oko 1 godina i ukupna doza Kladribina koja se daje tijekom te godine liječenja je oko 1.7 mg/kg, poželjno 1.75 mg/kg.
The organic portion is concentrated in vacuo and the resulting crude is purified on silica eluting with DCM/MeOH (20:1) to yield the titled compound. 
Organski dio se koncentrira u vakuumu i dobiveni sirov proizvod se očisti na silika gelu ispirući s DCM/MeOH (20:1), čime se dobije naslovni spoj.
X represents an oxygen atom or a sulfur atom, n, m is equal to 1 or 2; 
X predstavlja atom kisika ili atom sumpora; n i m iznose 1 ili 2;
ii) thioglycerol at a concentration of about 2.5 mg/mL; 
90% polietilen glikola i 10% propilen glikola; i ii) = tioglicerol u koncentraciji od 2.5 mg/mL.
DETAILED DESCRIPTION OF THE EMBODIMENTS OF THE INVENTION 
Datum podnošenja europske prijave patenta:
g of rifamicin SV are mixed with 5 g of stearic acid, 7 g of carnauba wax, 8 g of sodium dioctyl sulphosuccinate, 100 g of lactose and 10 g of sodium edetate and granulated with a solution containing 25 g of low-viscosity polyvinylpyrrolidone in 0.2 liter of purified water. 
Smjesa 200 g rifamicina SV sa 5 g stearinske kiseline, 7 g karnauba voska, 8 g natrij dioctil sulfosukcinata, 100 g laktoze i 10 g natrij edetata granulirana je otopinom koja sadrži 25 g polivinil pirolidona niske viskoznosti u 0,2 L pročišćene vode.
reducing the dry solids concentration of the hydrolyzed sludge by mixing dilution water with the hydrolyzed sludge at a point between the hydrolysis reactor and the anaerobic digester. The method of claim 1 including heating the hydrolysis reactor with steam produced by a steam generator; and directing steam generator feed water and hydrolyzed sludge to a heat exchanger disposed downstream of the hydrolysis reactor and reducing the temperature of the hydrolyzed sludge by transferring heat from the hydrolyzed sludge to the steam generator feed water. 
Postupak prema bilo kojem od patentnih zahtjeva 1-6 naznačeno time da se zagrijava reaktor za hidrolizu (214) parom proizvedenom u generatoru pare (212); i napojna vode generatora pare i hidrolizirani mulj se usmjerava prema izmjenjivaču topline smještenom nakon reaktora za hidrolizu (214) i gdje se snižava temperatura hidroliziranog mulja prijenosom topline od hidroliziranog mulja na napojnu vodu generatora pare.
In one embodiment of the invention there is provided a process in which the heated liquid is delivered to the radiator element located inside the poultry shed. 
Postupak prema zahtjevu 4 gdje se zagrijana tekućina dovodi do radijatora. Postupak prema zahtjevu 5 gdje se zagrijana tekućina dovodi do radijatora koji se nalazi unutar nastambe za perad.
The portion capsule as claimed in claim 1, wherein the capsule base has a predetermined breaking point which is intended to tear open as a result of mechanical contact with an external perforation means. 
Kapsula s porcijom (1) prema bilo kojem od prethodnih zahtjeva, naznačena time da je predodređena točka loma (104) namijenjena da se trga i otvara kao rezultat mehaničkog kontakta s vanjskim sredstvima za probijanje (16).
Every lamella 3 and 4 forms a rectangle with a short side 6 having a length of almost 20 mm and a long side 7 of some 30 mm. 
Svaka od lamela 3 i 4 tvore pravi kut s kratkom stranom 6 koja ima duljinu od približno 20 mm, a duga strana 7 ima duljinu od kojih 30 mm.
Use according to claims 15-17 wherein the medicament is In the form of eye drops, wherein the compound of formula 1 1' or 1" is dissolved or suspended in suitable solvent. 
Upotreba u skladu s patentnim zahtjevima 15-17, naznačena time što medikament je u obliku kapi za oči, gdje spoj formule T ili I" je otopljen ili suspendiran u pogodnom otapalu, 19.
The pharmaceutical composition of claim 1, wherein said compound is a modulator for use in the treatment of cystic fibrosis, wherein it has effect on mutant CFTR protein, wherein said CFTR mutation is a mutation AF508-CFTR, or another mutation of class II. 
Modulator formule (I) u skladu s patentnim zahtjevom 1, za uporabu u liječenju cistične fibroze pri čemu on ima učinak na mutirani CFTR protein, pri čemu je navedena mutacija CFTR mutacija ∆F508-CFTR, ili druga mutacije klase II.
The medicament may be used for inducing an immune response, in particular a cellular immune response, more particularly a T-cell mediated immune response against cells of solid tumors, which cells express a human class II MHC molecule on their surface and present a polypeptide comprising an amino acid sequence disclosed in SEQ ID NO:1-49. 
Upotreba tumoru pridruženih peptida prema bilo kojem od Zahtjeva 1 do 3 ili nukleinske kiseline prema Zahtjevu 4 staničnog imunološkog odgovora, specifičnije za imunološki odgovor posredovan T limfocitima protiv stanica solidnih tumora koje eksprimiraju humane MHC molekule razreda II na svojoj površini te prikazuju polipeptid koji se sastoji od slijeda aminokiselina navedenog u bilo kojem od Zahljeva 1 ili 2.
After recrystallisation from tetrahydrofuran, 17.5 g white crystals of 1 were obtained having m.p. 
Nakon rekristalizacije iz tetrahidrofurana, dobiva se 17,5 g bijelih kristala spoja 1 st. t.
A composition comprising an effective amount of a compound of paragraph 1, or a pharmaceutically acceptable salt of said compound; and an acceptable carrier. 
Pripravak naznačen time da sadrži učinkovitu količinu spoja prema zahtjevu 1, ili farmaceutski prihvatljivu sol navedenog spoja; i prihvatljiv nosač.
The composition for use according to claim 1, wherein the composition is for use in a method of treating or preventing a disease or condition selected from the group consisting of uveitis; multiple sclerosis; arthritis, such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn's disease or ulcerative colitis; celiac disease; asthma, such as allergic asthma or neutrophilic asthma; chronic obstructive pulmonary disease (COPD); scleritis; vasculitis; Behcet's disease; atherosclerosis; atopic dermatitis; emphysema; periodontitis; allergic rhinitis; and allograft rejection. 
Pripravak za upotrebu prema zahtjevu 1, naznačen time što je pripravak za upotrebu u postupku liječenja ili sprječavanja bolesti ili stanja izabranih iz grupe koju čine uveitis; multipla skleroza; artritis, kao što je reumatoidni artritis, osteoartritis, psorijatičmi artritis, ili juvenilni idiopatski artritis; neuromijelitis optika (Devicova bolest); ankilozantni spondilitis; spondiloartritis; psorijaza; sistemski eritemski lupus; upalna bolest crijeva, kao što je Crohnova bolest ili ulcerozni kolitis; celijakija; astma, kao što je alergijska astma ili neutrofilna astma; kronična opstruktivna plućna bolest (KOPB); skleritis; vaskulitis; Behcetova bolest; ateroskleroza; atopijski dermatitis; emfizem; periodontitis; alergijski rinitis; i odbacivanje presatka.
By the term “substantially solvent free and water free” is meant that the composite material comprises less than 4.0%, such as less than 1.0% or less than 0.5%, by weight of solvents and/or water. 
Prema terminu "uglavnom bez otapala i bez vode" znači da kompozitni materijal sadrži manje od 4.0% kao što je manje od 1.0% ili manje od 0.5% po masi otapala i/ili vode.
and R5 for each occurrence is, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; n is an integer selected from 0-4; p is 0, 1, or 2; and 
i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; n je cijeli broj odabran od 0-4; p je 0, 1, ili 2; i u je 0, 1, ili 2.
In making the compositions of the present invention, the active ingredient will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of a capsule, sachet, paper or other container. 
Kod priprave pripravaka prema ovom izumu aktivni sastojak se obično miješa s podlogom, ili razrjeđuje podlogom, ili uklapa u podlogu, te može biti u obliku kapsule, vrećice, papira ili kojeg drugog spremnika.
The composition of claim 2 having, at M3 or T2 or T4 no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5 um. 
Kompozicija stabilizirana magnezij kloridom prema patentnom zahtjevu 5 koja ima, u prosjeku, ne više od 10 000 čestica ispod granice vidljivosti po mL, koje imaju veličinu veću od 5 um.
The process of claim 6, wherein testing was performed at one of the following stages of manufacture: infection, growth stages, harvest, processing, splitting, surface protein extraction, and therapeutic or vaccine formulation. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se testiranje provodi kod jednog od sljedećih stupnjeva: virusna infekcija, stadiji rasta, prikupljanje virusa, procesuiranje virusa, razdvajanje, ekstrakcija membranskih proteina, formuliranje cjepiva, pakiranje cjepiva.
A fermenter according to claim 1, wherein the accumulation means (7) is comprised of the vat (2) itself. 
Fermentor u skladu sa patentnim zahtjevom 1, gdje sredstva za akumulaciju (7) su sačinjena od same posude (2).
A method according to claim 8, wherein the disease or condition is asthma. A method according to claim 8, wherein the disease or condition is chronic obstructive pulmonary disease (COPD). 
Pripravak za primjenu prema zahtjevu 8 ili 9, naznačen time, što je bolest 1li stanje astma ili kronična opstruktivna plućna bolest (COPD).
a Caspase domain or a functionally active variant thereof and 
domenu kaspaze koja može inducirati apoptozu i
coupling a compound of formula 2 (X = Cl, Br) with suitable boronic acids or boronic acid esters of formula 3 wherein R' is hydrogen or lower alkyl, to afford compounds of formula I wherein R is hydrogen, and, if desired, converting the obtained compound into pharmaceutically acceptable acid addition salts or into a compound of formula I, wherein R is tritium,; 
R N Fo i. pri čemu je R vodik, te ako je poželjno, pretvaranje dobivenog spoja u farmaceutski prihvatljive kiselinske adicijske soli ili u spoj formule I, pri čemu je R tricij; ili spajanje spoja formule 4
Then, the column was equilibrated by flushing through the column 5 or more BV of equilibration buffer, 1 mM MES pH 6.0±0.2, conductivity 45±15 µS/cm. 
Tada, kolona je bila uravnotežena ispiranjem s 5 ili više BV uravnotežujućeg pufera, ImM MES-a pH 6.0+ 0.2, provodljivost 45+15 uS/cm.
use of a compound of the present invention for the preparation of a medicament for treating a neoplastic disease. 
Uporaba formule sukladno patentnom zahtjevu 1, radi pripreme medikamenta u liječenju neoplastične bolesti kod pojedinca.
System according to one of claims from 1 to 12, wherein said operating unit (11) is so configured as to alert said central unit (15) repeatedly at given intervals from the first alert. 
Sustav prema jednom od zahtjeva od 1 do 11, naznačen time da je navedena radna jedinica (11) konfigurirana tako da upozorava navedenu centralnu jedinicu (15) opetovano u zadanim intervalima od prvog upozorenja.
An LED module of claim 12, wherein said module circuit includes a inverting circuit that is regulated according to the gain of said amplifying circuit. An LED module comprising: 
LED modul iz patentnog zahtjeva 27, naznačen time, da navedeni sklop modula sadržava premjesni koji se regulira u skladu s pojačanjem navedenog pojačivačkog sklopa.
In this synthesis is obtained a high yield without the need of purifying product 3 for later use. Then, the naphthyl derivative 3 is used as acylating agent. The compound 3 is selective for primary amino groups, such as linear or branched aliphatic diamines (ethylenediamine, propylenediamine, 2-ethylenediamine, butylenediamine) and polyfunctional amines such as a-amino acids; thioamines, amino alcohols and aminocarboxylic acids (a-aminoisobutyric acid, 2-aminoethanethiol, ethanolamine, B-alanine, 6-aminohexanoico acid, etc.). 
Postupak za pripremu derivata naftalena strukture I, prema zahtjevima 1 i 2, koji u Ry nose neku kiselinsku ili amino terminalnu skupinu, naznačen reakcijom acilacijskog sredstva, N-hidroksisukcinamid estera 4-(1- naftalimino)-4-oksobutanoične kiseline prema zahtjevu 4, pri čemu spojevi imaju primarne amino skupine kao što su alifatski diamini, linearni ili razgranati, i polifunkcionalne amine kao što su a-amino kiseline, tioamini, aminoalkoholi i aminokarboksilne kiseline, u prisutnosti neke organske baze ili bez nje, u DMF-u ili 1,4-dioksanu kao otapalu.
Preferably, in the method according to the present invention the composition of the atmosphere in step b) is adjusted on the basis of the partial pressure of oxygen of the atmosphere of the treatment furnace detected by pressure analyzers. 
Postupak u skladu s jednim od patentnih zahtjeva 1 i 2, naznačen time, da se sastav atmosfere u peći za obradu u koraku b) podešava pomoću programabilnog logičkog kontrolera (PLC).
and R3 are each, independently, selected from the group consisting of hydrogen, hydroxyl, C1-C3-alkyl, C3-C8-cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted C1-C3-alkyl, substituted C3-C8-cycloalkyl, substituted heterocyclyl, substituted aryl and substituted heteroaryl; 
svaki od R2 i R3 je neovisno odabran iz skupine koju čine: vodik, hidroksil, C1-C3-alkil, C3-C8-cikloalkil, heterociklil, aril, heteroaril, supstituirani C1-C3-alkil, supstituirani C3-C8-cikloalkil, supstituirani heterociklil, supstituirani aril i supstituirani heteroaril;
A modified serpin according to clause 7 wherein the P1' residue is mutated to Q, H, K or R. 
Modificirani serpin prema zahtjevu 1, naznačen time, da ostatak P1' je mutiran na K ili Q.
Use according to claim 19, wherein the amount of C12 to C36 aliphatic alcohol or acid is at least 5 %, more preferred at least 10 % (by wt), more preferred at least 15 % (by wt) and most preferred 20 % to 25 % (by wt) of the matrix formulation. 
Uporaba prema zahtjevu 13, gdje je količina C;> to Cag alifatskog alkohola ili kiseline barem 5%, poželjno barem 10% (težinski), poželjnije barem 15% (težinski) i najpoželjnije 20% do 25% (težinski) formulacije matriksa.
The monodisperse composition of claim 9, wherein the compound is B-6-CH3-(OCH2CH2)7-O-naloxol or pharmaceutically acceptable salt thereof. 
B-6-CH;-(OCH2CH>);-O-naloksol; ili farmaceutski prihvatljivu sol istih.
4-Methyl-5-(4-pyridazinyl)-2,4-dihydro-3 H -1,2,4-triazole-3-thione, as intermediate in the preparation of the compound of formula (I) according to claim 5. 
-[(3-klorpropil)tiol-4-metil-5-(4-metil-1,3-oksazol-5-il)-4H-1,2,4-triazol [image], naznačen time što je međuprodukt u dobivanju spoja formule (I) u skladu s patentnim zahtjevom 7.